Clinical Trials Logo

Clinical Trial Summary

The ichthyoses are a group of lifelong genetic disorders that share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. The vast majority are orphan disorders and are associated with extremely poor quality of life related to social ostracism from altered appearance, associated itchiness and discomfort, and functional limitations from the skin disease. Among the more common "orphan" forms of ichthyosis are autosomal recessive congenital ichthyosis (ARCI; includes lamellar ichthyosis/LI and congenital ichthyosiform erythroderma/CIE), Netherton syndrome (NS) and epidermolytic ichthyosis (EI). However, there are dozens of other syndromic and non-syndromic ichthyotic disorders as well. Therapy is time-consuming for patients or parents and is supportive, focusing on clearance of the scaling. There are no therapies based on our growing understanding of what causes the disease. We have recently found marked elevations in Th17/IL-23 pathway cytokines and chemokines in the skin of individuals with ichthyosis, most similar to the inflammatory pattern of psoriasis. While the significance of the high expression of Th17/IL-23 pathway genes across all forms of ichthyosis studied to date is unknown, the high expression of genes of the Th17/IL-23 pathway in psoriasis is thought to be causative for the disease manifestations. We propose that IL-12/IL-23 -targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life. As a proof-of-concept study, we propose to treat children (6 years of age and higher) and adults with ichthyotic disorders with ustekinumab in an open-label trial to serially assess clinical response to and safety of ustekinumab for this group of disorders.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04549792
Study type Interventional
Source Northwestern University
Status Active, not recruiting
Phase Early Phase 1
Start date April 1, 2021
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT00004690 - Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis Phase 3
Completed NCT00074685 - National Registry for Ichthyosis and Related Disorders
Completed NCT03641261 - Therapeutic Education Using an Internet Application in Hereditary Ichthyosis N/A
Completed NCT03796052 - Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients N/A
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Active, not recruiting NCT05295732 - The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis Phase 3
Terminated NCT02655861 - A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Recruiting NCT03464994 - Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO) N/A
Recruiting NCT03417856 - Defining the Skin and Blood Biomarkers of Ichthyosis
Terminated NCT04697056 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Phase 2
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Completed NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Phase 2
Not yet recruiting NCT06362447 - Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Phase 2